Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.

Keywords: Hodgkin lymphoma; first salvage therapy; autologous stem cell transplantation; brentuximab vedotin; bendamustine EN Hodgkin lymphoma first salvage therapy autologous stem cell transplantation brentuximab vedotin bendamustine e86 e90 5 04/30/20 20200501 NES 200501 We report the final 3-year efficacy and safety outcomes from a trial of outpatient administration of brentuximab vedotin (BV) plus bendamustine as a first salvage regimen in relapsed/refractory Hodgkin lymphoma (HL). Of 25 patients who underwent ASCT and six who did not continue BV monotherapy; 17 patients completed the maximum allowed 16 cycles of BV monotherapy. At the end of follow-up, 25 patients (83-3%) had no residual PN or Grade 1 PN, four patients had ongoing Grade 2 PN, and one patient had ongoing Grade 3 PN. [Extracted from the article]